HOʻolaha ʻo SIFI i ka hoʻolaha ʻana o ka EPICOLIN, KOKUʻĀ PIʻI I KA LĀMAʻI O GLAUCOMA.

ʻO SIFI, kahi hui lāʻau lapaʻau alakaʻi i ka hoʻomohala ʻana i nā hopena hou no ka mālama ʻana i nā maʻi o ka maka, hauʻoli e hoʻolaha i ka hoʻolaha ʻana o EpiColin, ke kākoʻo piha i hoʻolaʻa ʻia i nā maʻi glaucoma.

ʻO SIFI, alakaʻi i ka hui lāʻau lapaʻau i ka hoʻomohala ʻana i nā hopena hou no ka mālama ʻana i nā maʻi o ka maka, Ua hauʻoli e hoʻolaha i ka hoʻolaha ʻana o EpiColin, kākoʻo piha i hoʻolaʻa ʻia i nā maʻi glaucoma. Ma hope o Amiriox a me Ecbirio, ua uku hou ʻia nā lāʻau hypotonizing e ka NHS, ʻO EpiColin ke kolu o ka hana hou ma ka wahi lapaʻau glaucoma i hoʻokomo ʻia e SIFI i ka hapa lua o 2022.

He aha ka Epicolin

ʻO EpiColin kahi pākuʻi meaʻai ma muli o ka mea kanu extracts o Coleus forskohlii a me ka 'ōmaʻomaʻo kī, me Citicoline, Homotaurine, Group B huaora a me ka wikamina E, he waiwai hoʻohui i hypotonizing therapy no ka mālama 'ana i ka glaucoma, he mau maʻi degenerative.

"Ua ʻike ʻia i kēia manawa ʻaʻole ʻo ke kaomi ʻana o ka maka ke kumu pilikia no ka holomua glaucoma." wahi a ka ʻO Kauka Matteo Sacchi, ke poʻo o ka Glaucoma Center o ka University Eye Clinic, San Giuseppe Hospital - IRCCS MultiMedica, Milana, me ka ʻaha kūkā aupuni hou i hoʻolaʻa ʻia no ka glaucoma, "Ke hoʻomau ʻia nei ka nānā ʻana i nā mea e like me ke koʻikoʻi oxidative, neuroinflammation a me ka mitochondrial dysfunction, e hōʻoia ana i ke koʻikoʻi o kahi ala lapaʻau synergistic hou e pili ana i kahi ʻike pōkole a lōʻihi o ka mea maʻi."

I nā poʻe maʻi e loaʻa ana i ka glaucoma hiki i ka maʻi ke holomua ʻoiai ka emi ʻana o ke kaomi intra-ocular^1-3, a no laila pono e kākoʻo i ka lāʻau lapaʻau e pale a hoʻopaneʻe paha i kēia kaʻina degenerative o nā ʻāpana retinal^4,5. Ua hoʻolālā ʻia ka mea hoʻopihapiha therapeutic piha ʻo EpiColin e hana i kahi hopena neuroprotective a me ka hopena antioxidant mahalo i ka hana synergistic o kēlā me kēia ʻāpana, ʻike ʻia a hilinaʻi hoʻi, e kākoʻo i ka hypotonizing therapy. Ua hōʻike ʻia ka hopena neuroprotective o nā nutraceuticals ma nā haʻawina preclinical in vitro a me in vivo, a ma nā noiʻi lāʻau lapaʻau.⁶.

Wahi a nā kuhi hou, ma Italia aia ma kahi o 550.000 mau maʻi i hōʻoia ʻia e pili ana i ka glaucoma me kahi maʻi e piʻi aʻe me ka makahiki, e pili ana i ka 10% o nā mea ma luna o 70 mau makahiki. Ua manaʻo ʻia i nā makahiki he 20 e hiki mai ana he 33% ka piʻi ʻana o nā hihia i hoʻopaʻa ʻia ma Italia me nā kiʻekiʻe o 50% ma nā wahi i manaʻo ʻia ai ka ʻelemakule.^7_.

GLAUKOMA

ʻO ka glaucoma kahi maʻi maka e pili pinepine ana i ke kiʻekiʻe o ka maka. Wahi a ka WHO, ma kahi o 60 miliona mau kānaka i pili i ka honua⁸. ʻO ia ke kumu ʻelua o ka makapō ma ka pae honua ma hope o ka cataracts, akā ʻo ia ka mea mua i hiki ʻole ke hoʻololi ʻia.⁹.

AMIRIOX™ a me ECBIRIO™ ʻO Amiriox ™ (bimatoprost 0,3 mg / ml) a me Ecbirio™ (bimatoprost 0,3 mg / ml + timolol 5 mg / ml), ʻo ia ka monotherapy hou a me nā kulu maka paʻa i ʻae ʻia no ka hoʻohaʻahaʻa ʻana i ke kaomi intraocular kiʻekiʻe i ke kihi ākea ākea. nā maʻi e loaʻa ana i ka glaucoma a me ka ocular hypertension. Loaʻa ʻo Amiriox ™ a me Ecbirio ™ i loko o kahi hoʻolālā multidose preservative-free e mālama ai i ka ʻili ocular, kūpono a hiki i ʻekolu mahina ma hope o ka wehe ʻana.

BlogInnovazione.it